

Howard A. Zucker, M.D., J.D. Acting Commissioner of Health

Sue Kelly Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective July 16, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

 Dovonex Cream, Duetact, Epivir tablet, Tegretol XR and Ziagen tablet will be removed from the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 7/3/14):

Accolate	Evista	Pulmicort Respules
Adderall XR	Felbatol	Solaraze
Alphagan P 0.15%	Focalin XR(15mg,30mg,45mg)	Soriatane
Aldara	Gabitril 2mg, 4mg	Symbyax
Astepro	Hepsera	Tegretol suspension
Bactroban cream	Kadian	ТОВІ
Carbatrol	Lidoderm	Tobradex
Catapres-TTS	Lovenox	Toprol XL
Combivir	Mepron	Trileptal suspension
Cymbalta	Myfortic	Trizivir
Depakote sprinkle	Niaspan	Vancocin
Diastat	Ortho Evra	Wellbutrin
Diovan HCT	Prevpac	Wellbutrin XL
Epivir HBV	Prograf	

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.

